LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p

Yongjie Xin1,2*, Xu He1,2*, Wei Zhao2*, Meixiao Zhan2, Yong Li2, Jing Xiao2, Ke He3,4,5, Ligong Lu1,2

1Department of Interventional Oncology, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, P. R. China; 2Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, Guangdong, P. R. China; 3Department of General Surgery, Guangdong Second Provincial General Hospital, Southern Medical University, Haizhu District, Guangzhou, Guangdong, P. R. China; 4Department of Biochemistry, Zhongshan School of Medicine, Guangzhou, Guangdong, P. R. China; 5Center for Stem Cell Biology and Tissue Engineering, Key Laboratory of Ministry of Education, Sun Yat-sen University, Guangzhou 510080, Guangdong, P. R. China. *Equal contributors.

Abstract: Long non-coding RNAs (lncRNAs) act important roles in several tumors including cholangiocarcinoma. However, the expression pattern and function of PCAT6 in intrahepatic cholangiocarcinoma remains unknown. In our research, we showed that the PCAT6 expression level was upregulated in intrahepatic cholangiocarcinoma cell lines. The expression of PCAT6 in intrahepatic cholangiocarcinoma tissues than that in noncancerous samples and the higher expression of PCAT6 was associated with advanced stage. Ectopic expression of PCAT6 induced cell proliferation and invasion in cholangiocarcinoma cell. Moreover, we demonstrated that PCAT6 interacts with miR-330-5p by directly targeting and PCAT6 overexpression inhibited the expression of miR-330-5p in the ICC-9810 cell. We also showed that the expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared to noncancerous tissues. Interesting, we proved that the miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma. Ectopic expression of miR-330-5p suppressed cell proliferation and invasion. Finally, we showed that PCAT6 induced cell proliferation and invasion by decreasing miR-330-5p in cholangiocarcinoma cell. Taken together, these data suggested that lncRNA PCAT6 was an oncogenic player in the development of intrahepatic cholangiocarcinoma.

Keywords: Intrahepatic cholangiocarcinoma, PCAT6, miR-330-5p, oncogene

Introduction

Cholangiocarcinoma is one epithelial tumor of biliary tree and is the 2nd most frequent primary hepatic malignancy [1-4]. Despite the incidence of extrahepatic cholangiocarcinoma has maintained stable, the rate of intrahepatic cholangiocarcinoma has risen [5-7]. Although amelioration in therapy has been developed, the survival of these patients remains dissatisfied [8-11]. The majority of cholangiocarcinoma patients are diagnosed at advanced stages and surgery resection is not a viable alternative [1, 12-16]. Therefore, it is necessary to study the molecular mechanisms of cholangiocarcinoma and find some new biomarkers for diagnosis of cholangiocarcinoma.
PCAT6 induces cholangiocarcinoma progression

In our research, we showed that the PCAT6 expression level was upregulated in intrahepatic cholangiocarcinoma cell lines. The expression of PCAT6 in intrahepatic cholangiocarcinoma tissues than that in non-cancerous samples and the higher expression of PCAT6 was associated with advanced stage of intrahepatic cholangiocarcinoma. PCAT6 overexpression induced cell proliferation and invasion in cholangiocarcinoma cell.

Materials and methods

Tissue samples

Human intrahepatic cholangiocarcinoma tissues and non-tumorous tissues were collected from Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences (Guangdong, China). These samples were frozen in liquid nitrogen until use. This research was approved by the Ethics Committee of Guangdong General Hospital, Guangdong Academy of Medical Sciences (Guangdong, China). Informed consent was written by each patient.

Cell lines cultured and transfection

Human cholangiocarcinoma cell line (ICC-9810) was purchased from ATCC (American Type Culture Collection, VA, USA) and cultured in the RPMI-1640 medium containing FBS (fetal bovine serum, Gibco, USA). pcDNA-PCAT6 and control vector, miR-330-5p mimic and scramble were purchased from RiboBi company (Guangzhou, China). ICC-9810 cell was transfected by using Lipofectamine-2000 (Invitrogen, USA) following to the manufacturer's information.

RNA extraction and qRT-PCR analyses

Total cell and tissues' RNA was isolated using Trizol kit (Invitrogen, VA, USA) and cDNAs were composed with the Superscript II reverse kit following to manufacturer's description. Quantitative real-time PCR (qRT-PCR) assay was performed to measure the expression of PCAT6 and miR-330-5p using SYBR Green kit (TaKaRa, Dalian) on the LightCycler 480 system (Roche Applied Science, Switzerland). GAPDH and U6 were exploited as the internal control reference for mRNA and miRNA respectively. The primers were shown as following: U6 (forward: CTGCCTTCGCAGCACAC, reverse: AACGCTTCAGAATTGGC), PCAT6 (forward: 5'-CTCCTATTCCGTCCAATCC-3', reverse: 5'-GAAGCAGAGCAAGCAGAG-3'), GAPDH (forward: 5'-GGAGCGAGATCCTCCAAT-3', reverse: 5'-AGTCTTCCACGATACCA-3').

Cell proliferation and invasion

Cell growth was analyzed with Cell Counting Kit-8 (CCK-8, Japan) according to instruction. These cells were plated in the 96-well culture dish and cultured for 24, 48 and 72 hours. Ten μl CCK-8 liquid was added into the each well and the absorbance at the 450 nm was detected by using Thermo reader (Thermo Fisher Scientific). For cell invasion, Transwell chambers with Matrigel were used. ICC-9810 cells were plated in the upper chambers with serum RPMI-1640 medium and FBS was added to the lower chamber. After 48 hours, the invasive cells were fixed with methanol and then stained with the crystal violet. Cells were visualized and photographed under microscope.

 Luciferase reporter assay

The pGL3-PCAT6 mutant (PCAT6-mut) and pGL3-PCAT6 wild (PCAT6-wt) vectors were synthesized by PCAT6 cDNA fragment insertion which contained mutated or wild binding sites of miR-330-5p into the pGL3 luciferase reporter vectors. ICC-9810 cells were co-transfected with PCAT6-mut or PCAT6-wt and miR-330-5p mimic or scramble with Lipofectamine-2000 (Invitrogen, USA). The luciferase activities were analyzed with Dual Luciferase Reporter (Promega, USA).

Statistical analysis

Statistical assay was calculated using SPSS (version 18, Chicago, USA) and P value <0.05 was deemed to statistically significant difference. Data were showed as mean ± Standard Deviation (SD). Difference between 2 groups was compared by using Two-way student’s t-test. One-way ANOVA was exploiting to explore the significant differences between multiple groups.
PCAT6 induces cholangiocarcinoma progression

Results

PCAT6 was upregulated in intrahepatic cholangiocarcinoma tissues and cell lines

First, we investigated the expression level of PCAT6 in intrahepatic cholangiocarcinoma samples and noncancerous tissues. As shown in the Figure 1A, the PCAT6 level in intrahepatic cholangiocarcinoma cell lines (ICC-9810, CCLP1, HuCC-T1 and QBC939) was higher than that of nonmalignant cholangiocyte cell (BEC). The expression level of PCAT6 in intrahepatic cholangiocarcinoma samples was upregulated compared with noncancerous tissues (Figure 1B). The PCAT6 expression level was upregulated in 76.7% of (23/30) tumor tissues compared to noncancerous samples (Figure 1C). Moreover, we showed that the PCAT6 expression was higher in the stage III and IV than that in stage I and II of intrahepatic cholangiocarcinoma (Figure 1D).

PCAT6 overexpression induced cell proliferation and invasion in cholangiocarcinoma cells

Ecotropic expression of PCAT6 using pcDNA-PCAT6 and the PCAT6 expression level was measured to validate the efficiency of this vector (Figure 2A). Elevated expression of PCAT6 promoted cell growth of CCA cell line ICC-9810 (Figure 2B). Further, we proved that PCAT6 increased the expression of ki-67 and cyclin D1 in the ICC-9810 cell (Figure 2C and 2D). In addition, we demonstrated that the invasive ability was markedly increased in the PCAT6 overexpressing cells (Figure 2E and 2F).

PCAT6 interacts with miR-330-5p by directly targeting

Bioinformatics assay targetscan (http://www.targetscan.org/vert_72/) was used to predict that there are putative binding sites between miR-330-5p and PCAT6 (Figure 3A). Ectopic
PCAT6 induces cholangiocarcinoma progression

Figure 2. PCAT6 overexpression induced cell proliferation and invasion in cholangiocarcinoma cells. A. The expression of PCAT6 in the ICC-9810 cell after treated with pcDNA-PCAT6 was measured by qRT-PCR assay. B. Elevated expression of PCAT6 promoted cell growth of CCA cell line ICC-9810. C. The expression of ki-67 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. D. The expression of cyclin D1 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. E. The invasive ability was markedly increased in the PCAT6 overexpressing cells. F. The relative invasive cells were shown. **P<0.01 and ***P<0.001.
PCAT6 induces cholangiocarcinoma progression

expression of PCAT6 suppressed the expression of miR-330-5p in the ICC-9810 cell (Figure 3B). In addition, we validated that the miR-330-5p expression was significantly upregulated in the ICC-9810 cell after treating miR-330-5p mimic (Figure 3C). The luciferase activity of wt-PCAT6 transfected cell was suppressed by overexpression of miR-330-5p; however there is no change of mut-PCAT6 (Figure 3D). Overexpression of miR-330-5p decreased the PCAT6 expression in the ICC-9810 cell (Figure 3E).

miR-330-5p was downregulated in intrahepatic cholangiocarcinoma tissues

Then, we studied the expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples and noncancerous tissues. The expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared with noncancerous tissues (Figure 4A). The miR-330-5p expression level was downregulated in 66.7% of (20/30) tumor tissues compared to noncancerous samples (Figure 4B). Moreover, we showed that the miR-330-5p expression was lower in the stage III and IV than that in stage I and II of intrahepatic cholangiocarcinoma (Figure 4C). Interestingly, we indicated that the miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma (Figure 4D).

Ectopic expression of miR-330-5p inhibited cell proliferation and invasion

Elevated expression of miR-330-5p inhibited cell growth of CCA cell line ICC-9810 (Figure 5A). Further, we proved that miR-330-5p decreased the expression of ki-67 and cyclin D1 in the ICC-9810 cell (Figure 5B and 5C). In addition, we indicated that the invasive ability was markedly decreased in the miR-330-5p overexpressing cells (Figure 5D and 5E).

PCAT6 enhanced cell proliferation and invasion through decreasing miR-330-5p in cholangiocarcinoma cells

Next, we studied the impact role of miR-330-5p on PCAT6-induced proliferation and invasion of cholangiocarcinoma cell. As indicated in the Figure 6A, overexpression of miR-330-5p suppressed the cell proliferation in the ICC-9810 cell that was transfected with pcDNA-PCAT6. Moreover, elevated expression of miR-330-5p
PCAT6 induces cholangiocarcinoma progression

Figure 4. miR-330-5p was downregulated in intrahepatic cholangiocarcinoma tissues. A. The expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared with noncancerous tissues. B. The miR-330-5p expression level in intrahepatic cholangiocarcinoma samples and noncancerous tissues was shown as log2. C. The miR-330-5p expression was lower in the stage III and IV than that in stage I and II of intrahepatic cholangiocarcinoma. D. The miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma. **P<0.01.
PCAT6 induces cholangiocarcinoma progression

Figure 5. Ectopic expression of miR-330-5p inhibited cell proliferation and invasion. A. Elevated expression of miR-330-5p inhibited cell growth of CCA cell line ICC-9810. B. The expression of ki-67 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. C. The expression of cyclin D1 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. D. The invasive ability was markedly decreased in the miR-330-5p overexpressing cells. E. The relative invasive cells were shown. *P<0.05, **P<0.01 and ***P<0.001.

inhibited the ki-67 and cyclin D1 expression in the PCAT6-overexpressing ICC-9810 cell (Figure 6B and 6C). In addition, we showed that ectopic expression of miR-330-5p suppressed the cell invasion in the PCAT6-overexpressing ICC-9810 cell (Figure 6D and 6E).

Discussion

The current research showed that the PCAT6 expression level was upregulated in intrahepatic cholangiocarcinoma cell lines. The expression of PCAT6 in intrahepatic cholangiocarcinoma tissues than that in noncancerous samples and the higer expression of PCAT6 was associated with advanced stage of intrahepatic cholangiocarcinoma. PCAT6 overexpression induced cell proliferation and invasion in cholangiocarcinoma cell. Moreover, we showed that PCAT6 interacts with miR-330-5p by directly targeting and ectopic expression of PCAT6 suppressed the expression of miR-330-5p in the ICC-9810 cell. We also demonstrated that the expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared with noncancerous tissues.

Interesting, we indicated that the miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma. Ectopic expression of miR-330-5p inhibited cell proliferation and invasion. Finally, we showed that PCAT6 enhanced cell proliferation and invasion through decreasing miR-330-5p in cholangiocarcinoma cell. Taken together, these data suggested that lncRNA PCAT6 was an oncogenic player in the development of intrahepatic cholangiocarcinoma.

Growing evidences indicated that LncRNA PCAT6 was upregulated and played as oncogenic roles in several cancers including lung cancer, gastric cancer and colon cancer [32-34]. Aberrant upregulated PCAT6 was found to be in lung cancer and knockdown of PCAT6 suppressed lung cancer cell metastasis and proliferation and induced cell apoptosis [31]. Xu et al. [33] demonstrated that PCAT6 expression was upregulated in gastric tumor tissues and ectopic expression of PCAT6 induced cell invasion, proliferation and migration partly through regulating miR-30 expression. Huang et al. [34] reported that PCAT6 expression level was over-
PCAT6 induces cholangiocarcinoma progression

Figure 6. PCAT6 enhanced cell proliferation and invasion through decreasing miR-330-5p in cholangiocarcinoma cells. A. Overexpression of miR-330-5p suppressed the cell proliferation in the ICC-9810 cell that was transfected with pcDNA-PCAT6. B. The expression of ki-67 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. C. The expression of cyclin D1 was analyzed by qRT-PCR analysis and GAPDH was used as the internal control. D. Ectopic expression of miR-330-5p suppressed the cell invasion in the PCAT6-overexpressing ICC-9810 cell. E. The relative invasive cells were shown. *P<0.05, **P<0.01 and ***P<0.001.

expressed in colon cancer samples and higher expression of PCAT6 was correlated with worse survival status and poorer clinical stage. Overexpression of PCAT6 enhanced cell proliferation and suppressed cell apoptosis. However, the expression pattern of PCAT6 in intrahepatic cholangiocarcinoma remains unknown. First, we investigated the expression level of PCAT6 in intrahepatic cholangiocarcinoma samples and noncancerous tissues. We also found that PCAT6 expression level was upregulated in intrahepatic cholangiocarcinoma cell lines and tissues. In addition, we demonstrated that PCAT6 overexpression induced cell proliferation and invasion in cholangiocarcinoma cells.

The molecular mechanism via which PCAT6 induces tumor cell growth and invasion alters from different tumor species. Previous study indicated that PCAT6 induced lung tumor cell growth, invasion and migration via modulating miR-330-5p expression [35]. In line with this, we found that PCAT6 interacts with miR-330-5p by directly targeting and ectopic expression of PCAT6 suppressed the expression of miR-330-5p in the ICC-9810 cell. MiR-330-5p has been indicated to play suppressive roles in some cancers including glioblastoma, ovarian cancer, pancreatic cancer and cutaneous malignant melanoma [29, 36-38]. In line with this, we also found that expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared with noncancerous tissues. Interestingly, we indicated that the miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma. Ectopic expression of miR-330-5p inhibited cell proliferation and invasion. Furthermore, we showed that PCAT6 overexpression enhanced cell proliferation and invasion through decreasing miR-330-5p in cholangiocarcinoma cell.

Taken together, we demonstrated that the expression of PCAT6 was overexpressed in intrahepatic cholangiocarcinoma tissues and cell and ectopic expression of PCAT6 induced intrahepatic cholangiocarcinoma cell prolifera-
PCAT6 induces cholangiocarcinoma progression


PCAT6 induces cholangiocarcinoma progression


